The Network for Investigation of Delirium: Unifying Scientists (NIDUS)'s 9th-13th Annual Delirium Boot Camps: A Foundation for Future Exploration
- Institution
- UNIV OF NORTH CAROLINA CHAPEL HILL, NC
- Principal investigator
- Jan Busby-Whitehead
- Funding
- $50K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
Delirium is a serious cognitive disorder associated with Alzheimer’s disease and related dementias (ADRD) that affects ~2.6 million older adults yearly. It is a frequent complication of acute illness, surgery and, now, of COVID-19 infection in older adults. Recognizing the relative dearth of delirium research, the National Institute for Aging (NIA) supported the establishment of the Network for Investigation of Delirium: Unifying Scientists (NIDUS), a collaborative interdisciplinary group of 28 investigators, from 27 institutions, to advance delirium research and develop network infrastructure. This included the creation of an annual “NIDUS bootcamp” conference, to bring together the growing national- and international delirium research community for networking and education. The bootcamp aims are to advance the science of the field and to provide junior investigators with intensive mentorship, through mock NIH application reviews, clinical and research lectures, breakout sessions, and post-bootcamp networking. Bootcamp alumni are provided guidance on: 1) using the NIDUS Delirium Research Hub, Measurement resources and Bibliography, 2) submitting proposals to the NIDUS Pilot Program (13 one-year $50,000 grants awarded), NIA GEMSSTAR/CLINSTAR, the Alzheimer’s Association, and other foundations, 3) attending Mentoring webinars, 4) participating in Junior Faculty Working Groups, and 5) submitting research abstracts to the American Delirium Society (ADS) Annual Meeting. As PIs, 94 alumni have received 46 grants, of which 18 (40%) were NIH-funded, and published 265 original peer- reviewed articles. NIDUS has jumpstarted the careers of many young investigators, particularly bootcamp alumni, enabling them to launch independent programs in delirium research. The goal of this application is to support continuation of a yearly, themed Delirium Bootcamp Conference (DBC), to ensure that the progress of this active research community is sustained. The first-year theme will be the inter-relationship between delirium and ADRD. The Specific Aims are to: (1) Engage and support junior investigators in delirium research through mentorship and access to the NIDUS resources/network (2) Boost the researchers’ funding success (3) Facilitate publication of delirium research and provide ongoing mentorship, and (4) Facilitate networking among junior, mid-career, and senior researchers during and after DBC. As the pool of delirium investigators expands, there is a critical need for a conference focused on addressing cutting-edge research methods in all areas of delirium research, including the relationship with ADRD, “-Omics” research, machine learning and big data, innovations in randomized trials, animal models and mechanistic research, and clinical practice improvement. The DBC will provide an unparalleled opportunity to advance cutting-edge delirium research through interactive didactic sessions and in-depth guidance on complex and nuanced research methods essential for the highest caliber and most impactful delirium research.
Research team
- Jan Busby-WhiteheadPI
- John W. DevlinPI
LOADING MOONBASE SCORE
Questions for UNIV OF NORTH CAROLINA CHAPEL HILL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Univ of North Carolina Chapel HillNot yet scored
UNC-CH Summer Research Training in Aging for Medical Students
Jan Busby-Whitehead · $139K · 2010–2030
- NIH · Univ of North Carolina Chapel Hill65
Cortical circuits for the integration of parallel short-latency auditory pathways
Hiroyuki Kato · $469K · 2022–2027
- NIH · Univ of North Carolina Chapel Hill47
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy
Rick B Meeker · $638K · 2023–2029